Camellia Sinensis Leaf

Dosage for Camellia Sinensis Leaf extract is highly individualized and must be determined by a specialist (Allergist/Immunologist).

• For Skin Prick Testing: Typically, one drop of a 1:10 or 1:20 w/v (weight/volume) extract is applied to the skin, followed by a puncture with a sterile lancet.
• For Intradermal Testing: A much smaller volume (0.02 to 0.05 mL) of a highly diluted extract (e.g., 1:1000 w/v) is injected into the dermis.
• For Immunotherapy: The 'maintenance dose' is reached after a 'build-up phase.' Doses start extremely low (e.g., 0.05 mL of a 1:100,000 dilution) and are increased weekly until a maintenance concentration is achieved, usually 0.5 mL of a 1:100 or 1:10 dilution.

Camellia Sinensis Leaf extracts may be used in children, but extreme caution is required.

• Infants and Children: Skin testing is generally performed similarly to adults, though the number of tests performed at one time may be limited to reduce discomfort and the risk of systemic reactions.
• Safety: The safety of immunotherapy in children under the age of 5 has not been extensively established, and healthcare providers typically weigh the risks of anaphylaxis against the benefits of treatment.

Renal Impairment

No specific dosage adjustments are required for skin testing in patients with renal impairment, as systemic absorption is minimal. However, in patients with end-stage renal disease, skin reactivity may be slightly diminished (uremic pruritus/skin changes), potentially leading to false-negative results.

Hepatic Impairment

There are no documented dosage adjustments for hepatic impairment regarding the use of Camellia Sinensis Leaf extracts. The metabolism of small amounts of injected protein is not significantly affected by liver function.

Elderly Patients

In patients over age 65, skin reactivity to allergens often decreases. Healthcare providers may need to use intradermal testing more frequently to confirm a diagnosis. Additionally, elderly patients with pre-existing cardiovascular disease are at higher risk if a systemic reaction (anaphylaxis) occurs.

Camellia Sinensis Leaf extracts are never for self-administration. They must be administered by a trained healthcare professional in a clinical setting equipped with emergency resuscitation equipment.

1. 1Preparation: The skin (usually the forearm or back) is cleaned with alcohol.
2. 2Administration: For testing, the extract is applied to the skin surface. For immunotherapy, it is injected subcutaneously into the outer aspect of the upper arm.
3. 3Observation: Patients must remain in the clinic for at least 30 minutes following any administration to monitor for signs of a systemic allergic reaction.
4. 4Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should not be frozen.

If a dose of immunotherapy is missed, the patient should contact their allergist immediately.

• Short Delay: If the delay is only a few days, the same dose may be given.
• Long Delay: If several weeks have passed, the dose may need to be reduced to ensure safety, as the patient’s sensitivity may have increased.

An 'overdose' in the context of allergenic extracts refers to the administration of too much allergen, leading to a systemic reaction.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, and a drop in blood pressure (shock).
• Emergency Measures: Administration of Epinephrine (adrenaline) is the first-line treatment. Other measures include intravenous fluids, oxygen, and antihistamines.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most common side effects of Camellia Sinensis Leaf extract are localized to the site of administration.

• Local Wheal and Flare: This is the intended result of a positive skin test. It involves a raised, itchy bump (wheal) and surrounding redness (flare) that typically resolves within 1 to 2 hours.
• Injection Site Swelling: In immunotherapy, it is common to experience swelling and redness at the injection site that may last for 24 to 48 hours. This is often referred to as a 'local reaction.'
• Pruritus (Itching): Intense itching at the test site is very common and can be managed with topical cool compresses after the test is read.

• Delayed Local Reactions: Some patients experience swelling and redness that appears 6 to 12 hours after administration. While uncomfortable, these are usually not dangerous.
• Fatigue: Some patients report feeling unusually tired for several hours after receiving an allergen injection.
• Mild Rhinorrhea (Runny Nose): A slight increase in nasal congestion or sneezing may occur shortly after administration.

• Generalized Urticaria (Hives): Hives appearing on parts of the body far from the injection site indicate a systemic response.
• Vasovagal Reaction: Fainting or lightheadedness due to the needle stick or the sight of blood, rather than the extract itself.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site.

> Warning: Stop taking Camellia Sinensis Leaf treatments and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

• Respiratory Distress: Difficulty breathing, wheezing, or a high-pitched sound when breathing (stridor). This may indicate swelling of the airway.
• Angioedema: Significant swelling of the lips, tongue, or throat that can obstruct breathing.
• Hypotension (Low Blood Pressure): Feeling faint, dizzy, or losing consciousness. This can be a sign of anaphylactic shock.
• Tachycardia: A very rapid or pounding heartbeat.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

In the context of immunotherapy, long-term use is generally well-tolerated. However, there is a theoretical risk of:

• Persistent Sensitization: In rare cases, the very treatment meant to desensitize a patient could potentially maintain or slightly increase their sensitivity if not managed correctly.
• Subcutaneous Nodules: Small, hard lumps may form under the skin at the site of repeated injections. These are usually benign but should be monitored by a physician.

While Camellia Sinensis Leaf is a non-standardized extract, the FDA requires a general Black Box Warning for all allergenic extracts due to the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. These products should only be administered by healthcare professionals who are experienced in the diagnosis and treatment of allergic diseases and who are equipped to manage such reactions. Patients with unstable or severe asthma are at increased risk for life-threatening reactions. Patients should be observed for at least 30 minutes after each injection.

Report any unusual symptoms to your healthcare provider.

Camellia Sinensis Leaf extracts are potent biological materials. They are intended for use only by clinicians specialized in allergy and immunology. Patients must provide a full medical history, specifically highlighting any history of severe asthma or previous reactions to tea or other botanical extracts.

No FDA black box warnings specifically for Camellia Sinensis Leaf exist as a unique entity, but it falls under the mandatory class-wide black box warning for all Allergenic Extracts. This warning emphasizes that these extracts can cause anaphylaxis and must be administered in a medical setting with immediate access to epinephrine and airway management tools.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Any administration of the extract carries a risk of a systemic reaction. Risk is higher during the 'build-up' phase of immunotherapy or if the patient is currently experiencing an exacerbation of their allergies.
• Asthma Status: Patients with uncontrolled asthma should not undergo skin testing or receive immunotherapy until their asthma is stable. A bronchospasm (tightening of the airways) triggered by an allergen extract can be fatal in a patient with poor lung function.
• Beta-Blocker Use: Patients taking beta-blockers (medications for blood pressure or heart conditions) may be resistant to the effects of epinephrine, making an allergic reaction much harder to treat.
• ACE Inhibitor Use: Patients on ACE inhibitors may be at an increased risk for more severe systemic reactions.

• Observation Period: A strict 30-minute post-administration observation period is mandatory. Most fatal reactions occur within this window.
• Lung Function: For patients with asthma, a peak flow meter or spirometry may be used before administration to ensure the patient is at their baseline lung function.
• Skin Inspection: The site of administration should be checked for excessive local reactions before the patient leaves the clinic.

While the extract itself does not cause sedation, a systemic reaction or the subsequent administration of antihistamines or epinephrine can impair the ability to drive or operate machinery. Patients should ensure they feel completely normal before leaving the clinic and attempting to drive.

Alcohol consumption should be avoided for several hours before and after administration. Alcohol causes vasodilation (widening of blood vessels), which can potentially increase the rate of allergen absorption and increase the severity of a systemic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider will re-evaluate the risk-benefit ratio of continuing treatment. Immunotherapy is typically discontinued if the patient fails to show clinical improvement after an adequate period (usually 12–24 months) or if the reactions to the injections are consistently severe.

> Important: Discuss all your medical conditions with your healthcare provider before starting Camellia Sinensis Leaf.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are often considered a relative or absolute contraindication for allergen immunotherapy. In the event of anaphylaxis, beta-blockers prevent epinephrine from working effectively, which can lead to a treatment-resistant, fatal reaction.
• Severe Unstable Asthma: While not a drug, this condition is 'contraindicated' for testing. Testing during an asthma flare can trigger life-threatening respiratory failure.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These medications can interfere with the body's ability to degrade certain inflammatory mediators (like bradykinin), potentially making an allergic reaction more severe or prolonged.
• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine if it needs to be administered, leading to a risk of hypertensive crisis (dangerously high blood pressure).
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular effects of epinephrine.

• Antihistamines (H1 Blockers): Medications like cetirizine, loratadine, or diphenhydramine will suppress the skin's response to the allergen. This leads to a 'false negative' result. Patients must typically stop taking antihistamines for 3 to 7 days before skin testing.
• H2 Blockers (e.g., Famotidine): These may also slightly decrease skin reactivity and should be discontinued before testing if possible.
• Systemic Corticosteroids: Long-term use of oral steroids (like prednisone) can suppress the immune response and decrease skin test reactivity.

• Caffeine: High intake of caffeine (which is also found naturally in Camellia Sinensis) can increase heart rate and jitteriness, which may complicate the monitoring of a patient's vital signs during an allergic reaction.
• Alcohol: As noted previously, alcohol increases blood flow to the skin and can exacerbate the 'flare' reaction or speed up systemic absorption of an injected allergen.

• St. John's Wort: May interact with various medications used to treat anaphylaxis.
• Stimulant Herbs (e.g., Ephedra, Guarana): These can increase heart rate and blood pressure, potentially masking or complicating the symptoms of a systemic reaction.

• Skin Testing: The presence of the extract in the skin is the test itself. However, the use of Camellia Sinensis Leaf extract does not typically interfere with standard blood work (CBC, metabolic panels).
• IgE Testing: Recent administration of high-dose allergen extracts might theoretically affect the levels of specific IgE measured in the blood (ImmunoCap tests).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Prior Severe Anaphylaxis to Tea: If a patient has a history of a life-threatening reaction to Camellia Sinensis Leaf, skin testing or immunotherapy is generally strictly prohibited due to the extreme risk.
• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of their predicted value are at an unacceptably high risk for fatal bronchospasm during allergen administration.
• Acute Infection: Testing should not be performed if a patient has a fever or an active systemic infection, as the immune system is already in a heightened state.

• Pregnancy: While not an absolute contraindication for continuing a maintenance dose, it is generally recommended not to start new allergy testing or immunotherapy during pregnancy due to the risk of fetal hypoxia (lack of oxygen) if the mother has an anaphylactic reaction.
• Autoimmune Diseases: Patients with active autoimmune disorders may have unpredictable immune responses to allergen extracts.
• Malignancy: Patients with active cancer may have altered immune profiles that make immunotherapy less effective or more risky.
• Young Children (<5 years): The difficulty of communicating symptoms of a reaction makes testing and treatment more dangerous in this age group.

Patients allergic to Camellia Sinensis Leaf may show cross-reactivity with other members of the Theaceae family. There is also anecdotal evidence of cross-reactivity with certain pollens or other botanical extracts, though this is not well-standardized. Patients should inform their doctor if they have known allergies to other herbal products or specific botanical families.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Camellia Sinensis Leaf.

Camellia Sinensis Leaf extract is classified in the FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm. The primary risk during pregnancy is not the extract itself, but the potential for a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to maternal hypotension, which causes decreased uterine blood flow and fetal hypoxia (oxygen deprivation), potentially resulting in fetal death or brain damage. Therefore, starting immunotherapy during pregnancy is generally avoided. If a patient is already on a stable maintenance dose and becomes pregnant, the physician may choose to continue the treatment but will not increase the dose.

It is not known whether the allergenic proteins from Camellia Sinensis Leaf extract are excreted in human milk. However, since these are large protein molecules that are typically broken down at the site of injection or in the lymphatic system, it is unlikely that significant amounts reach the breast milk. The chemical constituents like caffeine and EGCG do pass into breast milk but in very small quantities when administered as an extract. The decision to continue treatment while breastfeeding should involve a risk-benefit analysis by the healthcare provider.

Skin testing with Camellia Sinensis Leaf is considered safe in children when performed by a specialist. However, the emotional and physical stress of the procedure must be managed. For immunotherapy, the 'approved' age is generally 5 years and older. Younger children may not be able to articulate the early symptoms of a systemic reaction (such as an itchy throat or 'feeling of doom'), which can delay the administration of life-saving epinephrine.

In patients over 65, the risk of complications from a systemic reaction is significantly higher due to the increased prevalence of cardiovascular and pulmonary diseases. Elderly patients are more likely to be taking medications like beta-blockers or ACE inhibitors, which complicate the management of anaphylaxis. Furthermore, skin reactivity decreases with age, which may lead to less reliable test results. Physicians often use lower starting doses and slower 'build-up' schedules for older adults.

There is no evidence that renal impairment significantly alters the response to or the safety of Camellia Sinensis Leaf allergenic extracts. Because the proteins are metabolized locally and systemically by proteases, the kidneys do not play a primary role in clearing the active allergen. However, uremia (buildup of toxins in the blood) can suppress skin test reactivity.

Liver disease does not typically affect the safety or efficacy of allergenic extracts. The liver's role in processing these specific proteins is minimal compared to its role in metabolizing small-molecule drugs. No specific dosage adjustments are recommended for patients with hepatic impairment.

> Important: Special populations require individualized medical assessment.

Camellia Sinensis Leaf extract acts as a diagnostic and therapeutic agent by interacting with the Type I Hypersensitivity pathway.

1. 1Diagnostic Phase: The extract contains specific protein allergens. When these proteins enter the skin, they cross-link IgE antibodies bound to FceRI receptors on mast cells. This triggers an influx of calcium ions, leading to the release of pre-formed mediators like histamine. This results in the 'wheal and flare' response within 15–20 minutes.
2. 2Therapeutic Phase (Immunotherapy): Repeated, escalating exposure to the extract induces a shift in the immune response from a Th2 (allergic) profile to a Th1 (regulatory) profile. This increases the production of T-regulatory cells and IgG4 'blocking' antibodies, which compete with IgE for allergen binding, eventually preventing the allergic cascade.

The pharmacodynamic effect is measured by the size of the skin reaction (wheal diameter). The dose-response relationship is logarithmic; small increases in concentration can lead to significantly larger skin reactions in sensitized individuals. The duration of the skin reaction is short (1–2 hours), but the immunological changes from immunotherapy can last for years.

| Parameter | Value |

|---|---|

| Bioavailability | Negligible (Skin Test); Slow/Partial (Subcutaneous) |

| Protein Binding | N/A (Proteins are degraded rather than bound) |

| Half-life | 2–5 hours (Chemical constituents); Minutes (Proteins) |

| Tmax | 15–20 minutes (Skin reaction); 1–3 hours (Systemic absorption) |

| Metabolism | Local and Systemic Proteolysis |

| Excretion | Renal (Metabolites of polyphenols); Fecal (Minimal) |

• Molecular Components: Includes proteins (allergens), polyphenols (Epigallocatechin gallate), methylxanthines (caffeine, theophylline), and the amino acid L-theanine.
• Solubility: Extracts are typically aqueous or glycerinated solutions.
• Structural Description: A complex mixture of botanical proteins and secondary metabolites derived from the leaves of the Camellia sinensis plant.

Camellia Sinensis Leaf belongs to the Allergenic Extracts therapeutic class. It is specifically categorized as a Non-Standardized Chemical Allergen [EPC]. Related medications include other botanical extracts like Oak, Grass, or Ragweed extracts used for similar diagnostic and therapeutic purposes.